Yantai Dongcheng Biochemicals paid $69.8 million to acquire the China assets of Global Medical Solutions, a US company that makes nuclear medicine and imaging contrast products. GMS, which operates mainly in Asia Pacific, described the transaction as a strategic partnership that will be positive for GMS in the long term. In addition, GMS said it would continue to operate in China even though the sale included all of its current China operations. GMS did not specify any details about the synergism it expects between itself and Dongcheng.
